ClinicalTrials.gg
Not yet recruitingNCT06538909StepuPUpdated Aug 6, 2024

Steps Against the Burden of Parkinson's Disease - StepuP

An interventional study of VR in Parkinson Disease, sponsored by Tel-Aviv Sourasky Medical Center. Not yet recruiting. Open to participants aged 25 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Tel-Aviv Sourasky Medical Center · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
25 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · Tel-Aviv Sourasky Medical Center.

Planned enrollment
13th of 14
21 · median 50
Started
2024
with 1 other
No phase
13 of 24
3 open now
Registered
22nd of 24
by date

Among the 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 with no phase, and was the 22nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 25 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center, or all of them as a file.
02

Study summary

The goals of our StepuP project are:

  1. To understand the kinematic and neural mechanisms underlying walking improvements due to treadmill training with and without VR-enabled gait adaptations in people with PD;
  2. To assess to what extent improvements in walking due to treadmill training, as measured in the laboratory, transfer to improvements in daily life mobility;
  3. To understand the mechanisms underlying the transfer from improvements in walking to improvements in mobility in daily life in people with PD;
  4. To understand for whom treadmill training improves walking characteristics in the laboratory and for whom it does not, and to understand for whom treadmill training improves mobility in daily life and for whom it does not.
03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
25 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Specific criteria for Parkinson's disease - PD

  • Diagnosis of Parkinson's disease according to the MDS World Movement Disorders Society criteria Disease severity H\&Y I-III
  • Score section 3.10 (ability to walk) MDS-UPDRS 3.10 ≥ 1
  • cognitive assessment > 15
  • Stable cardiovascular condition, ability to perform aerobic activity at low to moderate intensity
  • Without orthopedic diseases and other diseases that affect the quality of walking, at the decision of the researcher.

Exclusion criteria

Exclusion Criteria:

  • Moderate or severe depression (BDI-II ≥18)
  • Orthopedic diseases and other diseases that affect the quality of walking, at the decision of the researcher
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    PD with VR int.

    Parkinson's disease patients using Virtual reality intervention that include physical activity and cognitive

    Device: VR

Interventions

  • DeviceVR

    Virtual reality that simulates obstacles on the road during walking

    Also known as: Virtual Reality

06

What researchers measure

Primary outcomes

  1. motion capture

    Kinematic data will be collected using a Qualisys or Vicon motion capture system at a sampling frequency of 100 Hz.

    Time frame: 13 months

  2. describe brain activity by EEG cap

    EEG recordings will be made using a 64-channel or 128 channel EEG cap

    Time frame: 13 months

  3. describe muscles activity by EMG electrodes

    Bipolar EMG electrodes will be placed on the leg muscles. EMG data will be recorded at a sample frequency available for each system around 2000 Hz.

    Time frame: 13 months

Secondary outcomes

  1. clinical trial TUG

    standard time-up-and-go test

    Time frame: 13 months

  2. clinical trial walk test

    2-minute walk test

    Time frame: 13 months

  3. clinical trial MiniBESTest

    balance and fall risk

    Time frame: 13 months

  4. mGES questionnaire

    modified gait efficacy scale

    Time frame: 13 months

  5. FES-i questionnaire

    Short falls efficacy scale international FES-i

    Time frame: 13 months

  6. FACIT-F questionnaire

    fatigue

    Time frame: 13 months

  7. EQ-5D questionnaire

    health-related quality of life

    Time frame: 13 months

  8. Frailty questionnaire

    Frailty index for physical activity

    Time frame: 13 months

  9. Fall questionnaires

    Fall events (occurrence and frequency) and fall related injuries. (twelve-month retrospective during T0 and during the duration of the trail

    Time frame: 13 months

  10. MDS-UPDRS test

    MDS-UPDRS

    Time frame: 13 months

  11. NFOGQ questionnaires

    NFOGQ

    Time frame: 13 months

  12. aids questionnaires

    Use of mobility aids

    Time frame: 13 months

  13. cognition questionnaires

    MoCA and trail making test for cognition

    Time frame: 13 months

  14. Demographics questionnaire ( descriptive measures)

    General descriptive measures : Year of birth, gender, height, weight, shoe size, education, employment, living arrangement, smoking history and alcohol consumption.

    Time frame: 13 months

  15. Fracture history questionnaire

    Fracture history (number and type of fracture, twelve-month retrospective of T0)

    Time frame: 13 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Dec 2025, 15 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 15 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Aug 6, 2024
StartEst.
Sep 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06538909
Responsible party
Sponsor
First posted
Aug 6, 2024
Start date
Sep 2024 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Aug 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion